QIAGEN N.V. Overview
Pro stress-test →QIAGEN is a public biotechnology company (NYSE: QGEN) headquartered in Venlo, Netherlands, that delivers strong profitability through a diversified portfolio including sample preparation technologies, molecular diagnostics, and bioinformatics solutions. The company serves pharmaceutical, academic, and clinical markets with products spanning sample handling, PCR consumables, immunodiagnostics, and data interpretation platforms.
Strategic Profile
Pro stress-test →QIAGEN's growth pillars together grew 4% constant exchange rate (CER) in Q1 2026, with sample technologies delivering 9% CER growth driven by demand for automated consumables and instrument placements. The company updated its full-year 2026 outlook to 1-2% CER sales growth from the previously guided 5%, citing headwinds from reduced QuantiFERON immigration testing demand and sustained caution among U.S. Life Sciences customers.
Competitive Landscape
Pro stress-test →QIAGEN competes in the molecular diagnostics and sample preparation markets against diversified life sciences companies including Illumina (sequencing platforms), Bio-Rad Laboratories (molecular diagnostics consumables), and Abbott (point-of-care diagnostics), as well as specialized competitors in specific segments like bioMérieux (syndromic testing). The company's integrated offering spanning sample preparation through data interpretation provides competitive differentiation versus point-solution competitors.
Industry Context
QIAGEN N.V. operates in Molecular diagnostics and sample preparation.
Key facts
Founded: 1996 · Headquarters: Venlo, Netherlands · Employees: N/A · Revenue: $2.09B (2025) · Market cap: N/A